Literature DB >> 20223840

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis.

A W R van Kuijk, M de Groot, S O Stapel, B A C Dijkmans, G J Wolbink, P P Tak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20223840     DOI： 10.1136/ard.2009.108787

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  24 in total

1.  A series of patients on anti-TNF therapy referred to a multidisciplinary lung cancer service.

Authors:  C O'Connell; M Hensey; A B Mongey; D J Veale; S C Donnelly
Journal:  Ir J Med Sci       Date:  2012-04-11       Impact factor: 1.568

Review 2.  Psoriatic arthritis: latest treatments and their place in therapy.

Authors:  Eun Jin Kang; Arthur Kavanaugh
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

3.  IgG4 production against adalimumab during long term treatment of RA patients.

Authors:  Pauline A van Schouwenburg; Charlotte L Krieckaert; Michael Nurmohamed; Margreet Hart; Theo Rispens; Lucien Aarden; Diana Wouters; Gerrit Jan Wolbink
Journal:  J Clin Immunol       Date:  2012-05-24       Impact factor: 8.317

Review 4.  A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements.

Authors:  J M Sailstad; L Amaravadi; A Clements-Egan; B Gorovits; H A Myler; R C Pillutla; S Pursuhothama; M Putman; M K Rose; K Sonehara; L Tang; J T Wustner
Journal:  AAPS J       Date:  2014-03-29       Impact factor: 4.009

Review 5.  Tumor necrosis factor inhibitors in psoriatic arthritis.

Authors:  Santhi Mantravadi; Alexis Ogdie; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2017-05-22       Impact factor: 5.045

6.  Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations.

Authors:  Achille Marino; Feliciana Real-Fernández; Paolo Rovero; Teresa Giani; Ilaria Pagnini; Rolando Cimaz; Gabriele Simonini
Journal:  Clin Rheumatol       Date:  2018-03-05       Impact factor: 2.980

7.  Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Authors:  Peter Nash; Iain B McInnes; Philip J Mease; Howard Thom; Matthias Hunger; Andreas Karabis; Kunal Gandhi; Shephard Mpofu; Steffen M Jugl
Journal:  Rheumatol Ther       Date:  2018-03-31

Review 8.  Advances in rheumatology: new targeted therapeutics.

Authors:  Paul P Tak; Joachim R Kalden
Journal:  Arthritis Res Ther       Date:  2011-05-25       Impact factor: 5.156

9.  Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance Dose.

Authors:  Alexander A Navarini; Marco A Muster; Antonios G A Kolios; Philipp Fritsche; Martin Glatz; Lars E French; Ralph M Trüeb
Journal:  Case Rep Dermatol       Date:  2011-06-18

Review 10.  The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.

Authors:  Charlotte Louise Maria Krieckaert; Geertje Margret Bartelds; Willem Frederik Lems; Gerrit Jan Wolbink
Journal:  Arthritis Res Ther       Date:  2010-10-20       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.